VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene-driven non-small-cell lung cancers.

doi:10.1111/cas.14801

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene-driven non-small-cell lung cancers.

Cancer science - 1 May 2021

Watanabe Hiromi, Ichihara Eiki, Kayatani Hiroe, Makimoto Go, Ninomiya Kiichiro, Nishii Kazuya, Higo Hisao, Ando Chihiro, Okawa Sachi, Nakasuka Takamasa, Kano Hirohisa, Hara Naofumi, Hirabae Atsuko, Kato Yuka, Ninomiya Takashi, Kubo Toshio, Rai Kammei, Ohashi Kadoaki, Hotta Katsuyuki, Tabata Masahiro, Maeda Yoshinobu, Kiura Katsuyuki

Abstract excerpt

Molecular agents targeting the epidermal growth factor receptor (EGFR)-, anaplastic lymphoma kinase (ALK)- or c-ros oncogene 1 (ROS1) alterations have revolutionized the treatment of oncogene-driven non-small-cell lung cancer (NSCLC). However, the emergence of acquired resistance remains a significant challenge, limiting the wider clinical success of these molecular targeted therapies. In this study, we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to A549 Cells

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Angiogenesis Inhibitors

Share to Carbazoles

Share to Crizotinib

Share to Genes, erbB-1

Share to Heterografts

Share to Platelet Endothelial Cell Adhesion Molecule-1

Share to Vascular Endothelial Growth Factor Receptor-2

Source

Open in PubMed Open full text

Identifiers

PMID: 33410241
DOI: 10.1111/cas.14801
PMCID: PMC8088971

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene-driven non-small-cell lung cancers.PMID 33410241Read ↗

Mediating EGFR-TKI Resistance by VEGF/VEGFR Autocrine Pathway in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Dual inhibition of EGFR‑VEGF: An effective approach to the treatment of advanced non‑small cell lung cancer with EGFR mutation (Review).Semantic proximity Read ↗

Exploration on the first-line treatment of ERBB2-altered advanced non-small cell lung cancer: A multicenter retrospective study.Semantic proximity Read ↗

Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC.Semantic proximity Read ↗

Antitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human non-small-cell lung cancer xenograft models.Semantic proximity Read ↗

[New therapies for the treatment of advanced non-small cell lung cancer: inhibitors of the epidermal growth factor receptor and angiogenesis].Semantic proximity Read ↗

Role of VEGFA/VEGFR2 signaling in predicting clinical outcomes of EGFR-TKI treatment in EGFR-mutant non-small cell lung cancer.Semantic proximity Read ↗

CM082, a novel angiogenesis inhibitor, enhances the antitumor activity of gefitinib on epidermal growth factor receptor mutant non-small cell lung cancer in vitro and in vivo.Semantic proximity Read ↗

Clinicopathological impact of VEGFR2 and VEGF-C in patients with EGFR-major mutant NSCLC receiving osimertinib.Semantic proximity Read ↗

Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling.Semantic proximity Read ↗

Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer.Semantic proximity Read ↗

Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinic.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.